431990-11-3

Upstream product

• 431990-32-8 5-{3-[2-(tert-butyl-dimethyl-silanyloxymethyl)-5-oxo-pyrrolidin-1-yl]-prop-1-ynyl}-thiophene-2-carboxylic acid methyl ester 
• 431989-55-8 methyl 5-{3-[(2R)-2-(hydroxymethyl)-5-oxo-1-pyrrolidinyl]propyl}-2-thiophenecarboxylate 
• 431990-31-7 (R)-5-(t-butyldimethylsiloxymethyl)-1-(2-propynyl)-2-pyrrolidinone 
• 128899-30-9 (R)-5-(((tert-butyldimethylsilyl)oxy)methyl)pyrrolidin-2-one 
• 884490-86-2 5-(3-{2-oxo-5R-[3-oxo-4-(3-trifluoromethyl-phenyl)-but-1-enyl]-pyrrolidin-1-yl}-propyl)-thiophene-2-carboxylic acid methyl ester 
• 62224-19-5 5-bromo-2-thiophenecarboxylic acid methyl ester 

Relevant academic research and scientific papers

Discovery of highly selective EP4 receptor agonists that stimulate new bone formation and restore bone mass in ovariectomized rats

Heptanoic acid lactams, exemplified by 2, were identified as highly selective EP4 agonists via high throughput screening. Lead optimization led to the identification of lactams with a 30-fold increase in EP4 potency in vitro. Compounds demonstrated robust

Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist

The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-alkylidene-19-nor-vitamin D derivative and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof. Particularly, the present invention relates to pharmaceutical compositions and methods comprising administering to a patient in need thereof 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 and an EP2 or EP4 selective agonist or a pharmaceutically acceptable salt or prodrug thereof.